WASHINGTON — Everyone wants to know whether Michelle McMurry-Heath, the newly minted president of the Biotechnology Innovation Organization, will be President Biden’s pick to lead the Food and Drug Administration. And whether, quite frankly, she wants the job.
So STAT asked her just that — and asked, too, about the FDA’s controversial decision to approve Aduhelm for Alzheimer’s, and whether the drug industry should have gotten behind a high-profile, bipartisan drug pricing package it has opposed vehemently.
The transcript below has been edited for length and clarity.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
